Basilea Pharmaceutica AG
SIX:BSLN

Watchlist Manager
Basilea Pharmaceutica AG Logo
Basilea Pharmaceutica AG
SIX:BSLN
Watchlist
Price: 51.1 CHF -0.39% Market Closed
Market Cap: 619.4m CHF

Net Margin
Basilea Pharmaceutica AG

37.2%
Current
11%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
37.2%
=
Net Income
77.6m
/
Revenue
208.5m

Net Margin Across Competitors

Basilea Pharmaceutica AG
Glance View

Market Cap
617.8m CHF
Industry
Biotechnology

Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. The company is headquartered in Basel, Basel-Stadt and currently employs 154 full-time employees. The company went IPO on 2004-03-25. The firm operates in one segment, which is the discovery, development and commercialization of innovative pharmaceutical products to meet the needs of patients with cancer and infectious diseases. The company launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. Additionally It is conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in its portfolio.

BSLN Intrinsic Value
64.49 CHF
Undervaluation 21%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
37.2%
=
Net Income
77.6m
/
Revenue
208.5m
What is the Net Margin of Basilea Pharmaceutica AG?

Based on Basilea Pharmaceutica AG's most recent financial statements, the company has Net Margin of 37.2%.

Back to Top